{"filing":{"accession_number":"0001104659-26-106156","cik":"0001638287","ticker":"MTVA","company_name":"MetaVia Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"mtva-20260909x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926106156/mtva-20260909x8k.htm"},"events":[{"id":32249,"run_id":29629,"accession_number":"0001104659-26-106156","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"MetaVia disclosed preclinical study results for DA-1726 demonstrating tissue distribution and retention patterns that support the drug's once-weekly dosing profile and mechanism for obesity treatment. This material clinical milestone provides mechanistic rationale for the company's lead product candidate and supports ongoing Phase 1 development.","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35377,"accession_number":"0001104659-26-106156","item_number":"7.01","item_title":"Regulation FD Disclosures.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MetaVia disclosed preclinical study results for DA-1726 showing tissue distribution and retention patterns that support the drug's mechanism for obesity treatment. This is a material operational/clinical milestone for a clinical-stage biotech company, demonstrating mechanistic support for an ongoing Phase 1 program and providing rationale for the company's lead product candidate. While not a formal earnings release or regulatory approval, the disclosure of significant preclinical findings supporting clinical development is a material operational event that would affect investor assessment of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T13:01:40.806591+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35378,"accession_number":"0001104659-26-106156","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MetaVia announced preclinical study results for DA-1726 showing tissue distribution patterns and prolonged retention supporting its once-weekly dosing profile and biological rationale for waist circumference reduction. This is a material operational/clinical milestone for a clinical-stage biotech company, demonstrating mechanistic support for a lead product candidate. While not a formal earnings release, clinical trial results and preclinical findings are significant to investors evaluating the company's pipeline progress and product differentiation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T13:01:40.806591+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35377,"accession_number":"0001104659-26-106156","item_number":"7.01","item_title":"Regulation FD Disclosures.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MetaVia disclosed preclinical study results for DA-1726 showing tissue distribution and retention patterns that support the drug's mechanism for obesity treatment. This is a material operational/clinical milestone for a clinical-stage biotech company, demonstrating mechanistic support for an ongoing Phase 1 program and providing rationale for the company's lead product candidate. While not a formal earnings release or regulatory approval, the disclosure of significant preclinical findings supporting clinical development is a material operational event that would affect investor assessment of the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T13:01:40.806591+00:00","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-09-09"},{"id":35378,"accession_number":"0001104659-26-106156","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"MetaVia announced preclinical study results for DA-1726 showing tissue distribution patterns and prolonged retention supporting its once-weekly dosing profile and biological rationale for waist circumference reduction. This is a material operational/clinical milestone for a clinical-stage biotech company, demonstrating mechanistic support for a lead product candidate. While not a formal earnings release, clinical trial results and preclinical findings are significant to investors evaluating the company's pipeline progress and product differentiation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T13:01:40.806591+00:00","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-09-09"}]}